Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- FY2015 Japan Drug Spending Up 11% on Hep C Meds
September 15, 2016
- Industry Chiefs, Chuikyo Panelists Trade Barbs over Market Expansion on Add’l Indications
September 15, 2016
- 3 Pharma Groups Firmly Oppose Out-of-Cycle Re-Pricing at Chuikyo
September 15, 2016
- G-CSF Preparations Ordered to Add Anaphylaxis in ADR List
September 14, 2016
- Blue Book “Will Be Used as Reference When Selecting Generics”: Panel Chair
September 14, 2016
- PMDA, FDA, EMA Agree on 6 Regulatory Approaches on AMR
September 13, 2016
- G7 Health Ministers Adopt Kobe Communique
September 13, 2016
- Generics from 5 Companies Enough When Major Products Lose Patent Protection: Top Bureaucrat
September 13, 2016
- Kaketsuken “Should Seriously Reflect” on Its Conduct before Asking for Permission to Continue Business: Health Minister
September 12, 2016
- MHLW Panel Backs Approval of Pembrolizumab, Some Voice Concerns for Its High NHI Price
September 12, 2016
- MHLW Panel OKs Humira for Uveitis
September 12, 2016
- Kaketsuken’s Business Transfer Necessary: MHLW Official
September 9, 2016
- MHLW Reports Partial Modifications of Approval for 3 Drugs Including Polidocasklerol to Advisory Panel
September 9, 2016
- MHLW Panel Backs BI’s Triple Combo After 3rd Try
September 9, 2016
- NIBIOHN Strengthens Collaboration with Drug Makers to Promote Development of Japan-Originated Drugs
September 8, 2016
- MHLW Re-Stresses Caution over Use of EGFR TKIs in Opdivo-Treated Patients
September 7, 2016
- Barcode Labeling Increasing in Anticipation of Mandatory Use in 2021: MHLW Survey
September 6, 2016
- 6 National Centers Log Generic Use Rate of Average 73.8% in FY2015
September 6, 2016
- MHLW Issues Notification on Partial Revision of Rules for New Barcode Labeling to Be Required from April 2021
September 6, 2016
- PMDA to Host Int’l Seminars in 2017 under Asian Training Center Initiative
September 5, 2016
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…